Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases

Satô, Toshihiko; Watanabe, Atsushi; Kondo, Haruhiko; Kanzaki, Masato; Okubo, Kan; Yokoi, Kohei; Matsumoto, Kunio; Marutsuka, Takashi; Shinohara, Hirohiko; Teramukai, Satoshi; Kishi, Kazuma; Ebina, Masahito; Sugiyama, Yukihiko; Meinoshin, Okumora; Date, Hiroshi

doi:10.1016/j.jtcvs.2014.08.086

Cited by 120 publications

(108 citation statements)

References 22 publications

Supporting

Mentioning

103

Contrasting

Order By: Relevance

“…They concluded that history of AE, surgical procedure, UIP pattern in CT imaging, male gender, preoperative steroid use, elevated serum KL-6, and low vital capacity were risk factors for AE of IP in lung cancer patients following a pulmonary resection. In other reports, the same group also presented scores for predicting AE of IP following a lung resection [13] as well as their long-term results [14]. In our study, these factors, except for PP, were not found to significantly increase the risk of AE after lung resection.…”

Section: Discussionsupporting

confidence: 63%

Postoperative pyothorax a risk factor for acute exacerbation of idiopathic interstitial pneumonia following lung cancer resection

Kobayashi

Karube

Nishihira

et al. 2016

Gen Thorac Cardiovasc Surg

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 63%

Postoperative pyothorax a risk factor for acute exacerbation of idiopathic interstitial pneumonia following lung cancer resection

Kobayashi

Karube

Nishihira

et al. 2016

Gen Thorac Cardiovasc Surg

View full text Add to dashboard Cite

show abstract

“…Sublobectomy, including wedge resection and segmentectomy, is oncologically compromised resection of peribronchial, hilar, and mediastinal lymph nodes . Sublobectomy with low rates of nodal sampling could underestimate the tumor stage . Similarly, Robson et al reported that SBRT might be associated with significant regional control failure and worse outcomes as a result of occult pathological nodal metastasis.…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of PET/CT uptake for peripheral clinical N0 non‐small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

Objective In this cohort study, we determined the clinical value of the maximum standardized uptake value (SUVmax) of primary tumors in non‐small cell lung cancer (NSCLC). Study Design A retrospective review of NSCLC patients was performed from January 2011 to December 2017. Peripheral cN0 NSCLC patients with tumor size ≤2 cm were included. SUVmax was calculated as a continuous variable for semiquantitative analyses. A receiver operating characteristic curve was analyzed to assess the cutoff threshold of SUVmax on pathological (p) nodal metastasis. We further evaluated the clinical relevance of SUVmax in peripheral cN0 NSCLC patients. Results A total of 670 peripheral NSCLC patients with tumor size ≤2 cm were deemed cN0 by preoperative PET/CT scan. Statistical analyses suggested significant correlations of SUVmax with smoking status (P = .026), tumor volume (P = .001), pathology type (P = .008), tumor differentiation (P < .001), vessel invasion (P = .001), plural invasion (P < .001), pT stage (P < .001), nodal involvement (P < .001), and pathological tumor node metastasis stage (P < .001). A cutoff point of SUVmax of 3.8 (P < .001) could be used to predict pathological nodal metastasis. Multivariable analyses indicated that preoperative SUVmax >3.8 (odds ratio, 12.149; P < .001) was an independent predictor of nodal metastasis. Overall survival analyses further suggested that SUVmax was an independent prognostic indicator (hazard ratio, 2.050; P = .017). Conclusion Preoperative SUVmax is a predictor of pathological nodal metastasis and prognosis for peripheral cN0 NSCLC patients with tumor size ≤2 cm. Our results indicate that assessment of PET SUVmax could improve stratification of these patients.

show abstract

“…The approach using the 8-week volume decrease as an early marker is also applicable to cohorts treated with third-generation EGFR-TKIs, including rociletinib, AZD9291, and HM61713, in ongoing trials 35, 36 . The now validated association between the 8-week volume decrease and survival in the erlotinib or gefitinib treated cohorts may contribute to early assessment of the efficacy and therapeutic benefit of these novel agents, by providing additional information beyond the RECIST-based evaluations.…”

Section: Discussionmentioning

confidence: 99%

Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib

et al. 2016

View full text Add to dashboard Cite

Objective Investigate the association between 8-week tumor volume decrease and survival in an independent cohort of EGFR-mutant advanced non-small-cell lung cancer (NSCLC) patients treated with first-line erlotinib or gefitinib, and assess the rate of their volumetric tumor growth after the volume nadir. Methods In patients with advanced NSCLC harboring sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, CT tumor volumes of dominant lung lesions were analyzed for 1) the association with survival, and 2) volumetric tumor growth rate after the volume nadir. Results In 44 patients with the 8-week follow-up CT, the 8-week tumor volume decrease (%) was significantly associated with longer overall survival (OS) when fitted as a continuous variable in a Cox model (p=0.01). The growth rate of the logarithm of tumor volume (logeV), obtained using a linear mixed-effects model adjusting for time since baseline, was 0.096/month (SE:0.013/month; 95%CI:0.071-0.12/month), which was similar to the rate of 0.12/month (SE:0.015/month; 95%CI: 0.090-0.15/month) observed in the previous report. Conclusions The 8-week tumor volume decrease was validated as a marker for longer survival in the independent cohort of EGFR-mutant NSCLC patients treated with first-line erlotinib or gefitinib. Volumetric tumor growth rate after the nadir in this cohort was similar to that of the previous cohort, indicating the reproducibility of the observation among different patient cohorts.

show abstract

Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases

Cited by 120 publications

References 22 publications

Postoperative pyothorax a risk factor for acute exacerbation of idiopathic interstitial pneumonia following lung cancer resection

Postoperative pyothorax a risk factor for acute exacerbation of idiopathic interstitial pneumonia following lung cancer resection

Clinical significance of PET/CT uptake for peripheral clinical N0 non‐small cell lung cancer

Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib

Contact Info

Product

Resources

About